New drug combo may calm painful blisters in elderly skin disease
NCT ID NCT04563923
First seen Mar 26, 2026 · Last updated May 16, 2026 · Updated 7 times
Summary
This study tested whether adding avdoralimab (an antibody that blocks a specific immune signal) to strong steroid creams helps people with bullous pemphigoid, a blistering skin disease common in people over 70. Fifteen participants received the combination, and researchers measured how many achieved complete remission without relapse at 3 months. The goal is to find a safer, more targeted treatment that reduces reliance on steroids.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BULLOUS PEMPHIGOID are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
APHM, Hôpital Nord
Marseille, Bouches du rhône, 13000, France
-
APHM, Timone
Marseille, Bouche Du Rhône, 13005, France
-
CHU Montpellier, Dermatologie
Montpellier, Herault, 34005, France
-
CHU de Nice- Dermatologie
Nice, Alpes-Maritimes, 06200, France
Conditions
Explore the condition pages connected to this study.